Wikipedia -WSS

Wikipedia

author：focus 2025-10-01 12:30:22 Page View：8371

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb will pay $4.1 billion for RayzeBio, the companies said Tuesday, buying into the fast-growing field of using targeted doses of radiation to treat cancer.

RayzeBio, which raised about $350 million in a September initial public offering, is working in radiopharmaceuticals, which pair the tumor-killing power of radiation with the precision of targeted cancer therapies. The company is currently running a pivotal trial of its most advanced drug, RYZ101, in neuroendocrine cancer and has a pipeline of treatments for kidney, liver, and other cancers.

Bristol Myers will pay $62.50 in cash per share of RayzeBio, a roughly 115% premium to the company’s recent trading and more than triple the company’s IPO price.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How Vertex's cystic fibrosis drug is changing patients' lives
Next article： In age of alternative facts, a scholarly course on calling out crap

focus

How to save PrEP access — and even expand it

UndertheAffordableCareAct,healthinsurersarerequiredtocoverallcostsassociatedwithpreventivecare—inclu

EpiPen alternative approval delay highlights citizen petition issue

AlexWong/GettyImagesAmericanswhosuffersevereallergicreactionswon’thavealternativestoauto-injectorsli

Drug repurposing or repositioning? The language matters

AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

Senate HELP committee spars over health care workforce policies

Sen.BillCassidy(R-La.),left,andSen.BernieSanders(I-Vt.),right,clashedoverabilltoincreaseranksinthehe

Wikipedia

explore

focus

Senate HELP committee spars over health care workforce policies